Drug intelligence / Profile preview

oxycodone + lorazepam + fentanyl + midazolam

Development stage: Unknown
Lead developer: Purdue Pharma
Modality: Small Molecules
Administration: Oral, Intravenous, Intramuscular, Intranasal, Transdermal, Sublingual, Buccal, Transmucosal

Overview

This is a combination of four potent central nervous system depressants - two opioid analgesics (oxycodone and fentanyl) and two benzodiazepines (lorazepam and midazolam). This combination is not a standard commercial product but represents a dangerous polydrug combination with extremely high risk of severe respiratory depression, profound sedation, and potential fatal overdose. The FDA has issued boxed warnings about the life-threatening side effects when benzodiazepines are used with opioid medications.

Targets

GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on oxycodone + lorazepam + fentanyl + midazolam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxycodone + lorazepam + fentanyl + midazolam.

Explore the full profile